Hero MotoCorp shareholders approve ₹185 dividend and board reshuffle at 43rd AGM
Hero MotoCorp’s 43rd AGM concluded with shareholders approving FY26 financials and a ₹185 per share dividend. Re-appointments of Suman Kant Munjal and Dr. Pawan Munjal passed, but Dr. Munjal’s remuneration faced 20.38% dissent, largely from institutional investors. Promoter support remained unanimous across all resolutions.

*this image is generated using AI for illustrative purposes only.
Hero MotoCorp shareholders approved a total dividend payout of ₹185 per equity share for FY26 and ratified key board appointments at its 43rd Annual General Meeting (AGM) held on August 6, 2026. The virtual meeting, conducted via Video Conferencing/Other Audio Visual Means, saw high participation with over 85% of outstanding shares polled across all resolutions. While the adoption of financial statements and dividend declaration received near-unanimous support, the remuneration terms for Whole-time Director Dr. Pawan Munjal triggered notable dissent among institutional investors.
The AGM agenda included six resolutions, scrutinized by DPV & Associates LLP in compliance with Section 108 of the Companies Act, 2013 and Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. National Securities Depositories Limited (NSDL) facilitated the e-voting process. As of the record date, July 29, 2026, the company had 8,92,539 shareholders holding 20,00,92,938 equity shares. The promoter group, holding 6,94,88,181 shares, voted in favor of all resolutions without any dissent.
Voting Results Summary
The voting patterns revealed strong alignment on routine corporate governance matters but divergent views on executive compensation. The table below summarizes the aggregate voting outcomes for each resolution:
| Resolution Description | Type | Votes In Favour (%) | Votes Against (%) | Key Dissent Source |
|---|---|---|---|---|
| Adoption of Audited Financials (FY26) | Ordinary | 99.98% | 0.02% | Public Non-Institutions |
| Dividend Declaration (₹185/share) | Ordinary | 100.00% | 0.00% | Negligible |
| Re-appointment of Suman Kant Munjal | Ordinary | 97.45% | 2.55% | Public Institutions |
| Cost Auditor Remuneration (FY27) | Ordinary | 99.99% | 0.00% | Public Non-Institutions |
| Re-appointment of Dr. Pawan Munjal | Special | 96.82% | 3.18% | Public Institutions |
| Dr. Pawan Munjal’s Remuneration | Ordinary | 79.62% | 20.38% | Public Institutions |
Financial Statements and Dividend Approval
Shareholders unanimously endorsed the audited standalone and consolidated financial statements for the year ended March 31, 2026. The resolution to confirm the interim dividend of ₹110 per share and declare a final dividend of ₹75 per share for FY26 passed with 99.9999% support. Only 255 shares were voted against this resolution, all from public non-institutional categories. This indicates broad shareholder confidence in the company’s capital allocation strategy and financial health.
Board Appointments and Executive Compensation
The re-appointment of Suman Kant Munjal, who retires by rotation, passed with 97.45% support. However, 43,63,199 shares (2.55%) were voted against, primarily by public institutional investors who cast 43,60,740 dissenting votes. Similarly, the special resolution to re-appoint Dr. Pawan Munjal as Whole-time Director received 96.82% support, with 54,54,718 shares (3.18%) voting against. Again, public institutions formed the bulk of the dissent, casting 54,52,264 votes against the motion.
The most contentious item was the approval of Dr. Pawan Munjal’s remuneration terms. This ordinary resolution secured only 79.62% support, with 3,49,22,444 shares (20.38%) voting against. Public institutional investors drove this opposition, casting 3,49,17,117 dissenting votes compared to just 6,61,98,085 in favor. In contrast, public non-institutional investors supported the remuneration package with 99.27% assent. This divergence suggests specific concerns among large institutional holders regarding executive pay structures, despite overall confidence in leadership continuity.
What the Numbers Show
The voting data highlights a clear bifurcation in shareholder sentiment between routine operational approvals and executive compensation. While the promoter group and retail/non-institutional shareholders demonstrated near-total alignment with management on all fronts, public institutional investors exercised selective dissent. Their opposition to Dr. Pawan Munjal’s remuneration, while supporting his re-appointment, signals a nuanced stance: acceptance of leadership tenure but scrutiny of compensation metrics. This pattern is critical for future governance discussions, as it reflects growing institutional engagement in aligning executive pay with performance expectations.
Historical Stock Returns for Hero Motocorp
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.45% | +7.80% | +12.26% | -3.74% | +22.07% | +96.91% |
How might the 20% institutional dissent on Dr. Pawan Munjal's remuneration influence Hero MotoCorp's executive compensation structure for FY27?
What specific performance metrics or governance changes are public institutional investors likely to demand to align with their dissenting votes?
Could the bifurcation between promoter support and institutional scrutiny impact Hero MotoCorp's stock valuation or attract ESG-focused fund adjustments?


































